Paradigm Biopharmaceuticals Ltd.
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 51
- Market Cap
- -
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
Phase 3
Not yet recruiting
- Conditions
- Osteoarthritis, Knee
- Interventions
- Drug: Pentosan Polysulfate Sodium twice weeklyDrug: Placebo
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Paradigm Biopharmaceuticals Ltd.
- Target Recruit Count
- 466
- Registration Number
- NCT06917404
© Copyright 2025. All Rights Reserved by MedPath